Leap Therapeutics (NASDAQ:LPTX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a report published on Friday,Benzinga reports. They currently have a $5.50 target price on the stock.

Leap Therapeutics Trading Down 5.2 %

Shares of LPTX stock traded down $0.15 during trading hours on Friday, reaching $2.74. 322,359 shares of the stock were exchanged, compared to its average volume of 238,817. Leap Therapeutics has a 12-month low of $1.34 and a 12-month high of $5.00. The company’s 50-day moving average price is $2.94 and its 200-day moving average price is $2.58. The firm has a market capitalization of $70.14 million, a price-to-earnings ratio of -1.42 and a beta of 0.22.

Hedge Funds Weigh In On Leap Therapeutics

A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares in the last quarter. HighTower Advisors LLC bought a new stake in Leap Therapeutics during the 3rd quarter valued at about $65,000. Valence8 US LP bought a new stake in Leap Therapeutics during the 3rd quarter valued at about $48,000. Simplify Asset Management Inc. lifted its holdings in Leap Therapeutics by 67.4% during the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after buying an additional 425,626 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its holdings in Leap Therapeutics by 13.0% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after buying an additional 37,067 shares in the last quarter. 30.46% of the stock is owned by hedge funds and other institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.